A signaling pathway-driven bioinformatics pipeline for predicting therapeutics against emerging infectious diseases.
Tiana M ScottSam JensenBrett E PickettPublished in: F1000Research (2021)
Background: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the etiological agent of coronavirus disease-2019 (COVID-19), is a novel Betacoronavirus that was first reported in Wuhan, China in December of 2019. The virus has since caused a worldwide pandemic that highlights the need to quickly identify potential prophylactic or therapeutic treatments that can reduce the signs, symptoms, and/or spread of disease when dealing with a novel infectious agent. To combat this problem, we constructed a computational pipeline that uniquely combines existing tools to predict drugs and biologics that could be repurposed to combat an emerging pathogen. Methods: Our workflow analyzes RNA-sequencing data to determine differentially expressed genes, enriched Gene Ontology (GO) terms, and dysregulated pathways in infected cells, which can then be used to identify US Food and Drug Administration (FDA)-approved drugs that target human proteins within these pathways. We used this pipeline to perform a meta-analysis of RNA-seq data from cells infected with three Betacoronavirus species including severe acute respiratory syndrome coronavirus (SARS-CoV; SARS), Middle East respiratory syndrome coronavirus (MERS-CoV; MERS), and SARS-CoV-2, as well as respiratory syncytial virus and influenza A virus to identify therapeutics that could be used to treat COVID-19. Results: This analysis identified twelve existing drugs, most of which already have FDA-approval, that are predicted to counter the effects of SARS-CoV-2 infection. These results were cross-referenced with interventional clinical trials and other studies in the literature to identify drugs on our list that had previously been identified or used as treatments for COIVD-19 including canakinumab, anakinra, tocilizumab, sarilumab, and baricitinib. Conclusions: While the results reported here are specific to Betacoronaviruses, such as SARS-CoV-2, our bioinformatics pipeline can be used to quickly identify candidate therapeutics for future emerging infectious diseases.
Keyphrases
- respiratory syndrome coronavirus
- sars cov
- coronavirus disease
- infectious diseases
- drug administration
- induced apoptosis
- rna seq
- single cell
- signaling pathway
- clinical trial
- small molecule
- respiratory syncytial virus
- cell cycle arrest
- electronic health record
- genome wide
- endoplasmic reticulum stress
- endothelial cells
- systematic review
- rheumatoid arthritis
- pi k akt
- big data
- randomized controlled trial
- genome wide identification
- gene expression
- risk assessment
- human health
- systemic lupus erythematosus
- current status
- machine learning
- candida albicans
- copy number
- climate change
- physical activity
- depressive symptoms
- sleep quality
- pluripotent stem cells
- dna methylation
- study protocol
- double blind
- deep learning
- rheumatoid arthritis patients